Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sivelestat for COVID-19 ARDS
NCT05697016Unknown
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jan 2023
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
Randomised, double-blind trial in acute respiratory distress syndrome (ARDS) comparing Sivelestat Group with Placebo Group (2 arms). Primary endpoint: PaO2/FiO2 ratio at Day 7. Status: unknown.
02
Drugs
sivelestat
03
Conditions
acute respiratory distress syndrome (ARDS)
Beyond the preview
Go deeper on NCT05697016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05697016.